Zacks Investment Research upgraded shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) from a hold rating to a buy rating in a research report report published on Wednesday morning. They currently have $26.00 target price on the specialty pharmaceutical company’s stock.
According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
Several other analysts have also recently issued reports on the company. Jefferies Group reiterated a buy rating and issued a $28.00 price objective (up from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Northland Securities lowered Supernus Pharmaceuticals from an outperform rating to a market perform rating and set a $24.00 target price on the stock. in a report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an overweight rating to a neutral rating and set a $23.00 target price on the stock. in a report on Monday, July 18th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $25.25.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.05. The business had revenue of $50.40 million for the quarter, compared to analysts’ expectations of $49.67 million. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The company’s revenue for the quarter was up 43.6% compared to the same quarter last year. During the same period last year, the firm earned $0.03 earnings per share.
In related news, CFO Gregory S. Patrick sold 2,000 shares of the stock in a transaction on Friday, September 16th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now owns 3,616 shares of the company’s stock, valued at $90,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.10% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of SUPN. Macquarie Group Ltd. raised its position in Supernus Pharmaceuticals by 13.3% in the second quarter. Macquarie Group Ltd. now owns 145,504 shares of the specialty pharmaceutical company’s stock valued at $2,964,000 after buying an additional 17,104 shares during the period. Mason Street Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $138,000. Schwab Charles Investment Management Inc. raised its position in shares of Supernus Pharmaceuticals by 6.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 137,023 shares of the specialty pharmaceutical company’s stock valued at $2,792,000 after buying an additional 8,387 shares during the last quarter. Legal & General Group Plc raised its position in shares of Supernus Pharmaceuticals by 35.9% in the second quarter. Legal & General Group Plc now owns 7,282 shares of the specialty pharmaceutical company’s stock valued at $143,000 after buying an additional 1,924 shares during the last quarter. Finally, Fiera Capital Corp purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $27,544,000. 94.66% of the stock is currently owned by hedge funds and other institutional investors.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.